You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Fig. 4

Overall survival (OS) after the addition of pembrolizumab. The figures below describe the median OS from the start of pembrolizumab added to their respective kinase inhibitor (KI) therapy. From the date of addition of pembrolizumab, the median OS was 6.93 months (95% CI = 1.7, 12.15) (a). In the patients who were on dabrafenib plus trametinib while on pembrolizumab, the median OS was 3.8 months (95% CI = 2.5, 5.1). Similarly the median OS of the patients who were on the combination of lenvatinib plus pembrolizumab was 8.25 months (95% CI = 5.4, 11.1), from the start of pembrolizumab (b). The patient on trametinib is alive 4.9 months after starting pembrolizumab in addition to her trametinib

Back to article page